The CHMP also concluded that, after 18 months of treatment, the benefit seen with Leqembi on CDR-SB – a 1.21-point increase with the drug versus a 1.66-point rise with placebo – represented a ...
“We might be able to have a big impact.” Since January 2023, two new drug treatments — Leqembi made by Eisai and Biogen and Kisunla made by Eli Lilly — have been approved by the Food and ...